Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ACAD vs CRACU: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ACAD Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)

ACAD Overall Winner 6-Pillar Tally: ACAD 5 – 1 CRACU Matrix Metrics: ACAD 7 – 3 CRACU

As of Nov 20, 2026, Acadia Pharmaceuticals Inc. (ACAD) is the stronger overall head-to-head candidate over CRACU (CRACU) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ACAD carries a Unified Composite Score of 44.8/100 (HOLD) at $17.11 (15.8x Forward P/E, 10.2% operating margin), whereas CRACU carries 62.1/100 (BUY) at $10.45 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While CRACU currently prints a higher short-term Unified Composite Score (62.1/100 BUY vs. ACAD 44.8/100 HOLD), ACAD captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (10.2% vs. N/A operating margin) and revenue trajectory (+22.8% vs. N/A YoY).
  • Technical & Structure Timing Caution: ACAD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.2); meanwhile CRACU trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ACAD vs CRACU
ACAD NASDAQ Head-to-Head Winner
Acadia Pharmaceuticals Inc.
Pharmaceutical Preparations
$17.11
-2.73% 1D
Market Cap $3.0B
TTM Revenue $1.20B
Forward P/E 15.8x
Beta / 30D Vol 0.15β · 90% Vol
Unified Composite Score
44.8 / 100 HOLD
Tech 38.0 Fund 54.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.6%), weak momentum, RSI 34
RSI-14: 34.2 · SMA20: $19.31 · SMA50: $20.80
CRACU US Equity
CRACU
Institutional Equity
$10.45
+0.97% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.02β · 6% Vol
Unified Composite Score
62.1 / 100 BUY
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A

6-Pillar Scorecard Institutional Category Breakdown (ACAD 5 – 1 CRACU)

Columns: Metric · ACAD · CRACU
1. Valuation Multiples ACAD
Forward P/E 15.8x N/M
Trailing P/E 8.3x N/M
PEG Ratio N/M N/M
EV / Revenue 2.3x N/M
2. Growth & Scale ACAD
Revenue Growth (YoY) +22.8% N/A
Earnings Growth (YoY) -26.2% N/A
TTM Revenue (USD) $1.20B N/A
Market Cap $3.0B N/A
3. Profitability & Quality ACAD
Gross Margin 63.9% N/A
Operating Margin 10.2% N/A
Net Profit Margin 30.1% N/A
Return on Equity (ROE) 31.4% N/A
4. Balance Sheet & Cash Flow ACAD
Cash Generation (TTM) $181M N/A
Cash Flow Margin 15.0% N/A
Net Cash / Leverage $251M Net Cash N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CRACU
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 41.7% (6th %ile) N/A (N/A)
Put/Call OI Skew 71.82x (Put-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat ACAD
OpEx & R&D Intensity 53.7% of Rev ($646M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ACAD (7) vs CRACU (3)
Institutional Metric ACAD CRACU Criterion Row Edge
Market Capitalization
Scale
$3.0B N/A Larger Scale ACAD
Trailing P/E Ratio
Valuation
8.3x N/M Lower Multiple ACAD
Forward P/E Ratio
Valuation
15.8x N/M Lower Multiple ACAD
Revenue Growth (YoY)
Growth
+22.8% N/A Higher Growth ACAD
Operating Margin (TTM)
Profitability
10.2% N/A Higher Margin ACAD
Net Profit Margin
Profitability
30.1% N/A Higher Margin ACAD
Return on Equity (ROE)
Capital Efficiency
31.4% N/A Higher ROE ACAD
52-Week Range Position
Momentum
8% ($16–$31) 65% ($10–$11) Stronger Trend CRACU
Beta / 30D Volatility
Risk Regime
0.15β · 90% Vol -0.02β · 6% Vol Lower Realized Risk CRACU
Unified Institutional Score
Composite Signal
44.8 / 100 (HOLD) 62.1 / 100 (BUY) Higher Composite CRACU
Trailing 12M Revenue (USD)
Operating Scale
$1.20B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
63.9% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$181M ($251M Net Cash) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CRACU +19.8 pp
ACAD: -17.25% · CRACU: +2.55%
3M Horizon CRACU +24.34 pp
ACAD: -20.87% · CRACU: +3.47%
6M Horizon CRACU +24.34 pp
ACAD: -20.87% · CRACU: +3.47%
1Y Horizon CRACU +24.34 pp
ACAD: -20.87% · CRACU: +3.47%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACAD vs CRACU. Trailing 12-month operating profitability (ACAD 10.2% vs CRACU N/A) and valuation multiples (ACAD 15.8x vs CRACU N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ACAD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.20B
Gross Margin63.9%
Op. Margin10.2%
ROE / Fwd P/E31.4% · 15.8x
CRACU ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ACAD BREAKDOWN
62d in phase · OBV DISTRIBUTION
Current IV 41.7%
IV Percentile 6th %ile
Put/Call OI Skew 71.82x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact ACAD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CRACU UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CRACU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $18.67 · IV 48.0%

ACAD Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($1,867)

Compare $1,867 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 48.0% ATM IV.

PUT-WALL MONTHLY INCOME Liq B

Dec 18 $17 / $16 Bull Put Spread

Sell 3x $17P · Buy 3x $16P · 32d

Net Entry $75 Credit
Max Credit / Yield +$75 (+33.3% RoM)
Max Risk / Buffer -10.3% Cushion ($225 Mgn)
5d Edge & Liquidity 76% PoP · Liq B
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq B

Dec 18 $20 / $17 Bear Put Spread

Buy 1x $20P · Sell 1x $17P · 32d

Net Entry $85 Debit
T+5d @ -5% Drop +$54 (+64%)
Max Risk / Buffer $85 Capped
5d Edge & Liquidity 1.4x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ACAD Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $3.0B market capitalization and 10.2% operating margin.
OpEx & R&D Reinvestment 53.7% of Rev ($646M)
90D Engineering Disclosures 0 Published
CRACU Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ACAD vs CRACU Key Questions & Quantitative Answers

As of Nov 20, 2026, Acadia Pharmaceuticals Inc. (ACAD) is the stronger overall head-to-head candidate over CRACU (CRACU) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ACAD carries a Unified Composite Score of 44.8/100 (HOLD) at $17.11 (15.8x Forward P/E, 10.2% operating margin), whereas CRACU carries 62.1/100 (BUY) at $10.45 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While CRACU currently prints a higher short-term Unified Composite Score (62.1/100 BUY vs. ACAD 44.8/100 HOLD), ACAD captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (10.2% vs. N/A operating margin) and revenue trajectory (+22.8% vs. N/A YoY). Technical & Structure Timing Caution: ACAD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.2); meanwhile CRACU trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ACAD leads the Growth & Scale pillar: ACAD posts +22.8% YoY revenue growth and -26.2% YoY earnings growth on $1.20B TTM revenue (63.9% gross margin, 10.2% operating margin), compared with CRACU at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, ACAD generates $1.20B in USD-normalized revenue versus N/A for CRACU. In operating R&D and SG&A reinvestment, ACAD deploys 53.7% of Rev ($646M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CRACU.

ACAD screens cheaper on headline valuation multiples. ACAD trades at 15.8x Forward P/E, 8.3x Trailing P/E, N/M PEG, and 2.3x EV/Revenue (15.0% FCF margin), whereas CRACU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ACAD (31.4% ROE) versus CRACU (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, ACAD carries 41.7% implied volatility (6th %ile, Compressed (<25th %ile)), a 71.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.15β · 90% Vol realized risk). By comparison, CRACU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 6% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.